Melatonin has been implicated in several neurotropic effects, but few studies have investigated the bioavailability of melatonin in the brain. The discovery of periventricular sites of action adjacent to the third ventricle forced us to investigate the dynamics of cerebrospinal fluid (CSF) melatonin release and the source of this melatonin. Our first study demonstrated unequivocally that third ventricle CSF melatonin, like jugular plasma melatonin, accurately reflects the duration of the night and is rapidly suppressed by light. However, third ventricle CSF melatonin levels are 20-fold higher than nocturnal plasma concentrations. A further study showed that melatonin increased in plasma before third ventricle CSF, raising the possibility that melatonin is taken up from the blood after recirculation through the Galen vein. However, a final experiment suggested strongly that CSF melatonin is released directly into the third ventricle, as melatonin levels in the lateral ventricle were 7-fold lower than those in the third ventricle. Our study raises the possibility that there may be two compartments of melatonin affecting physiological functioning: the first in plasma acting on peripheral organs, and the second in the CSF affecting neurally mediated functions at a much higher concentration of this pineal indoleamine. (Endocrinology 140: 4399 -4405, 1999) M ELATONIN, the principal substance secreted by the pineal gland, has been implicated in a number of physiological functions. These include, among others, mood, sleep, circadian rhythms, the immune system, and reproduction (1, 2). In seasonally breeding mammals, there is unequivocal evidence that melatonin is the primary transducer of photoperiodic information to the neuroendocrine reproductive axis (for reviews, see Refs. 3 and 4). Recently, it has also been hypothesized that melatonin may play a role in memory formation (5) and may be important in pathological neurological disorders such as Alzheimer's and Parkinson's diseases (6 -9). Nevertheless, despite evidence implicating melatonin in these neurotropic effects, how and where melatonin acts remains poorly understood.
M ELATONIN, the principal substance secreted by the pineal gland, has been implicated in a number of physiological functions. These include, among others, mood, sleep, circadian rhythms, the immune system, and reproduction (1, 2) . In seasonally breeding mammals, there is unequivocal evidence that melatonin is the primary transducer of photoperiodic information to the neuroendocrine reproductive axis (for reviews, see Refs. 3 and 4) . Recently, it has also been hypothesized that melatonin may play a role in memory formation (5) and may be important in pathological neurological disorders such as Alzheimer's and Parkinson's diseases (6 -9) . Nevertheless, despite evidence implicating melatonin in these neurotropic effects, how and where melatonin acts remains poorly understood.
It is currently thought that melatonin reaches its neural targets via the peripheral circulation (10, 11) . According to this approach, melatonin is secreted into the Galen vein, which drains into the sagittal sinus before entering the jugular vein. Venous melatonin is finally transported back to the brain via the carotid arteries. Considering that the pineal gland is a deep brain structure, this route of action would appear rather circuitous. An alternative hypothesis is that melatonin reaches its targets through the cerebroventricular system. Data to support this second hypothesis are, however, sparse, and less than 0.1% of the total amount of melatonin produced by the pineal gland is thought to enter the cerebrospinal fluid (CSF) (12) .
Reported CSF melatonin concentrations vary enormously in the few studies published. Moreover, the majority of reports are based on cisternal (11) (12) (13) (14) or lumbar (15, 16 ) CSF samples, which consistently have concentrations similar to or lower than those found in blood. As this site of collection is somewhat distant from the cerebral ventricles, the concentrations present may not reflect levels found in the ventricles or, more importantly, the levels seen by neural tissue in target sites. Indeed, reports suggest that lateral ventricle CSF melatonin levels are higher than those in both plasma and cisternal/lumbar CSF (17) (18) (19) . However, there are no studies investigating CSF melatonin concentrations in the third ventricle; moreover, it is thought that melatonin is not secreted directly into this ventricle (17) . Our interest in this particular compartment of CSF has been raised by our discovery that the site of action responsible for transducing the effects of melatonin on reproduction are located in the premammillary hypothalamic area, a periventricular site extending laterally from the third ventricle by only 2 mm (20) .
Using a technique we developed recently to continuously withdraw CSF from the third ventricle for long periods (21) , the objective of our first study was to characterize third ventricular CSF melatonin concentrations over 24 h and compare these concentrations with levels found in jugular plasma. Further studies sought to establish whether melatonin enters the cerebral ventricular system directly from the pineal.
Materials and Methods General
Sexually mature Clun Forest (Exp 1 and 2) or Ile-de-France (Exp 3) ewes were housed in rooms with a photoperiod of 16 h of light followed by 8 h of darkness, had free access to water, and were fed daily with hay, straw, and corn. In all experiments, ewes were restrained so that they could not turn around, but were able to move forwards and backwards. To prevent the stress of social isolation, ewes were always in contact with other sheep. All procedures were carried out under Home Office Project License PPL 80/1037 or in accordance with Authorization A37801 of the French Ministry of Agriculture.
Ventricular surgery
At least 2 weeks before experimentation, a third ventricular guide cannula was permanently implanted using a method described in detail previously (21) . Briefly, the guide cannula was constructed from a stainless steel luer-lock needle, which had the tube end blunted and cut to a length of 40 mm. For placing the guide cannula, the head of the anesthetized ewe (halothane, Pitman-Moore France, Meaux, France) was positioned in a stereotaxic frame (Précision Cinématographique, Paris, France), and 1 ml radioopaque liquid (Omnipaque, Nycomed Ingenon SA, Paris, France) was injected into the lateral ventricle. Frontal and lateral x-rays were taken to give specific landmarks of the ventricular system, especially the thalamic mass intermedia and the infundibular recess of the third ventricle for the antero-posterior and vertical orientations and the middle of the third ventricle for the laterality of the cannula. Using the lateral x-ray, the cannula was aimed approximately 1 mm in front of and below the vertical and horizontal tangents, respectively, of the thalamic mass. When the tip of the cannula was in the third ventricle, CSF flowed freely back up the tube. The cannula was fixed to the skull with acrylic dental cement and, to maintain sterility and prevent CSF leakage, a plastic obturator was inserted into the cannula. A threaded cylindrical Teflon cap, anchored to the skull with four stainless steel screws and acrylic cement, protected the whole device. In Exp 3, a guide cannula was also placed in the lateral ventricle using the same approach.
CSF and jugular blood collection
Approximately 6 h before sample collection commenced, a catheter was inserted into the jugular vein and secured to the skin. The catheter was connected to polyethylene tubing, which was connected to a peristaltic pump. Animals were then injected with 25,000 IU heparin, and blood was continuously withdrawn into collection containers at a rate of 3-4 ml/10 min. Samples were centrifuged, and plasma was stored at Ϫ20 C until assay.
A SILASTIC brand catheter (Dow Corning Corp., Midland, MI) was inserted through the ventricular guide cannula so that the distal tip ended at the tip of the guide cannula. To collect a sample of CSF, the proximal end of the catheter was connected to approximately 1 m of PVC tubing, which, in turn, was connected to peristaltic tubing. The peristaltic tubing was threaded through a rate-adjustable peristaltic pump (Minipuls 2, Gilson, Villiers-le-bel, France), and CSF fractions were extracted for the desired period. For each ewe, the time taken for CSF to reach the fraction tubes was recorded, which enabled the true time the sample was extracted from the third ventricle to be calculated. Unless stated otherwise, CSF was collected at a rate of 30 l/min, and fractions were stored at Ϫ20 C until assayed.
Exp 1: profile of melatonin in third ventricular CSF
To characterize the nightly profile of melatonin in CSF, six ClunForest ewes were prepared for CSF collection as described. To obtain a prenight average, hourly sampling started 5 h before lights off and continued for 24 h. Half an hour before lights off, samples were collected every 3 min for the next 90 min. Similarly, 30 min before lights on, samples were collected every 3 min for the following 90 min. One hour of 3-min samples was also collected in the middle of the night to establish whether CSF melatonin release was pulsatile.
To determine the effect of CSF withdrawal on melatonin release, the flow rate was decreased (10 l/min) for the second night in four of the six ewes, during which hourly samples were collected. To see whether the light-mediated suppression of melatonin release, well established in plasma, also occurred in third ventricular CSF, the lights were turned on at midnight during the second night in the remaining two ewes. In these animals, CSF was collected in 3-min fractions for 30 min before and after lights on.
Exp 2: do CSF and plasma melatonin levels increase coincidentally?
In the previous experiment, it was apparent that the 3-min sampling regimen did not permit sufficient resolution of the time courses to determine whether melatonin increased simultaneously in the blood and the CSF or whether there was a time delay in a particular compartment. To investigate this further, six ewes were prepared for CSF and jugular blood collection as described. Half an hour before lights off, two 10-min samples were collected. Samples were collected every 30 sec for 50 min, starting 10 min before lights off. At the end of this period, two additional 10-min samples were collected to establish whether melatonin secretion was still increasing.
Exp 3: is melatonin released directly into the third ventricle?
The delay evident in the increase in CSF melatonin may have been a result of recirculation of melatonin through the choroid plexus and into the lateral ventricle. To test this hypothesis, five ewes were prepared for the simultaneous collection of CSF from the lateral and third ventricles. At the time of the experiment, it was possible to collect CSF simultaneously from both compartments in only three ewes. In these ewes, 30-sec samples were collected starting 10 min before lights off and continuing for an additional 40 min. At the end of the night, 30-sec CSF samples were collected from both compartments starting 10 min before lights on and continuing for an additional 40 min.
Melatonin assay
Jugular plasma melatonin concentrations were determined in 100-l aliquots, using a well validated RIA (22) . Melatonin concentrations in 2-to 30-l aliquots of CSF samples were measured in the same assay system, except that the standard curve was made in assay buffer instead of plasma. Parallelism between the standard curve and sample dilution was checked for volumes in the range 0 -50 l, and accuracy was checked by assaying melatonin after loading daytime samples with exogenous melatonin. In Exp 2, to eliminate the assay sensitivity difference caused by the higher melatonin concentrations in CSF, the daytime level in plasma and CSF was first determined. The volume of CSF that would yield the same amount as that found in 100 l plasma was then calculated, and samples of CSF corresponding to this volume were assayed simultaneously with 100-l plasma samples. Assay sensitivity averaged 0.4 pg/tube, and intra-and interassay sensitivities were 4% and 1.1%, respectively, for plasma and 6% and 13%, respectively, for CSF.
Analysis
The onset of the melatonin increase was taken as the time melatonin concentrations exceeded either the mean plus 3sd of samples collected during the hour preceding darkness or 3 times the assay sensitivity, whichever was the greatest. The offset was taken as the time melatonin concentrations fell below the mean Ϫ 1sd of samples collected during the hour preceding lights on. The time taken for CSF and plasma melatonin levels to reach 10% of the mean nocturnal level was also calculated in Exp 1. The nocturnal maximum and the mean concentration during darkness were determined using hourly values. Statistical comparisons between the two compartments were made using Student's t test for paired data, with significance set at P Ͻ 0.05. Pearson's correlation was performed to establish the relationship between the mean melatonin concentration in third ventricular CSF and plasma for Exp 1 and 2 combined (n ϭ 11).
FIG. 1.
Mean Ϯ SEM (n ϭ 6) concentrations of melatonin detectable in the CSF of the third ventricle (squares) and in the jugular plasma (circles). Note that although the pattern of melatonin concentrations in both compartments responded identically to the onset and offset of darkness, levels were 20-fold higher in the CSF. Insets show the mean Ϯ SEM melatonin in each compartment during the 3-min sampling regimen. The shaded area represents the period of darkness.
Results

Exp 1: profile of melatonin in third ventricular CSF
The hourly third ventricular CSF and jugular melatonin concentrations are shown in Fig. 1 . In both CSF and plasma, the duration of the night is accurately reflected by the increase in the duration of melatonin release. CSF melatonin increased above the concentration (34 Ϯ 4 pg/ ml) detected in the hour preceding lights off within 14 Ϯ 3 min of darkness and started to fall within 13 Ϯ 2 min of lights on. Similarly, plasma melatonin increased above a prenight baseline (5 Ϯ 1 pg/ml) within 10 Ϯ 3 min of darkness and started to fall within 8 Ϯ 3 min after lights on. Melatonin levels fell below 10% of the nocturnal mean after lights on in 39 Ϯ 4 and 36 Ϯ 4 min in the CSF and plasma, respectively.
In CSF, melatonin concentrations rose 34 Ϯ 5-fold from a daylight average of 71 Ϯ 8 pg/ml to a nocturnal maximum of 2136 Ϯ 303 pg/ml (mean, 1497 Ϯ 216 pg/ml). Similarly, plasma levels rose 27 Ϯ 6-fold from a daytime mean of 8 Ϯ 2 pg/ml to a maximum of 188 Ϯ 39 pg/ml (mean, 117 Ϯ 15 pg/ml). However, nocturnal CSF melatonin concentrations in the third ventricle were 19 Ϯ 8-fold (range, 6 -39) higher than levels in the jugular blood, and diurnal concentrations were 11 Ϯ 4-fold (range, 7-14) greater. There was no evidence of pulsatile release in either CSF or plasma.
Reducing the flow rate to 10 l/min during the second night did not affect the measurable level of melatonin in CSF (Fig. 2) . Neither the mean nightly CSF (night 1, 1327 Ϯ 106 pg/ml; night 2, 1175 Ϯ 196 pg/ml) nor plasma (night 1, 139 Ϯ 22 pg/ml; night 2, 110 Ϯ 12 pg/ml) level was significantly different over the 2 days. This suggests that the high melatonin concentrations in third ventricular CSF found in this study are not due to disturbances in the normal CSF flow pathway and that the withdrawal of CSF does not affect the neural circuitry involved in transmitting photic information to the pineal gland.
As expected, switching the lights on during the second night caused a rapid decrease in melatonin release in both CSF and plasma. This decline was indiscernible from the decrease observed after the usual light onset (data not shown). 
Exp 2: do CSF and plasma melatonin levels increase coincidentally?
Melatonin increased earlier in the plasma than in CSF in all six ewes (Fig. 3) . After a delay of only 7.8 Ϯ 1.7 min in the plasma, but 12.7 Ϯ 1.4 min in the CSF, melatonin levels increased significantly above their daytime baseline. This amounted to a significant (P Ͻ 0.05) delay of 4.9 Ϯ 1.1 min between the two compartments. As before, mean nocturnal CSF melatonin concentrations were significantly (21 Ϯ 8-fold; range, 7-62) higher than those found in plasma.
There was no correlation between the mean plasma melatonin level and that detected in CSF, indicating that plasma concentrations cannot be used as an index of CSF levels.
Exp 3: is melatonin released directly into the third ventricle?
In the three ewes from which it was possible to collect CSF from the lateral and third cerebral ventricles simultaneously, melatonin concentrations were 7 Ϯ 3 times higher in the third ventricle (Fig. 4) . In these ewes, melatonin concentrations averaged 2247 Ϯ 629 pg/ml in the third ventricle, but were only 525 Ϯ 212 pg/ml in the lateral ventricle. Melatonin levels also started to increase in the third ventricle before increasing in the lateral ventricle in all ewes (ewe 040, 8 vs. 9 min; ewe 120, 10 vs. 13 min; ewe 354, 26 vs. 50 min).
Discussion
This is the first study reporting the concentrations of melatonin in third ventricular CSF and, more importantly, the first to characterize the acute pattern of continuous release into CSF. Overall, nocturnal third ventricular CSF melatonin concentrations exceeded jugular and lateral ventricle levels by 20-and 7-fold, respectively. This latter discovery provides compelling evidence that the majority of melatonin detectable in the CSF comes directly from the pineal gland into the cerebroventricular system and not through retrograde flow in the great vein of Galen.
Our finding that CSF melatonin concentrations are significantly higher than plasma levels concurs with earlier studies on goats (18) and calves (17) , in which hourly to every 2 h instantaneous samples of lateral ventricle CSF were shown to exceed jugular plasma concentrations by between 5-and 18-fold. Similarly, in the sheep, hourly lateral ventricle CSF melatonin concentrations were reported to be up to 8-fold higher, whereas in the cisterna magna, CSF levels were comparable to those in plasma (19) . However, Rollag and coworkers (12) found that cisterna magna CSF melatonin levels in sheep were significantly lower than those in the plasma, which led these researchers to conclude that less than 0.1% of the total melatonin released by the pineal gland enters the cerebral ventricles. The results from the present study showing high concentrations of melatonin in the CSF as well as a rapid clearance of melatonin from the CSF after the lights had been switched on suggest very strongly that this figure needs to be reassessed.
How does melatonin get into the CSF? Early studies on humans and monkeys using lumbar or cisternal CSF suggested that melatonin entered the CSF from the blood (10, 11) . To explain reports that melatonin concentrations in the lateral ventricle were higher than those in the plasma (17, 18) , this hypothesis was subsequently refined to suggest that there was retrograde blood flow from the Galen vein to the choroid plexus (19, 23) . Upon reaching the choroid plexus, melatonin would simply diffuse down its concentration gradient into the lateral ventricle. Anatomical evidence showing connections between the choroid plexus and the Galen vein lent support to this hypothesis (24, 25) . Indeed, as melatonin increased in the jugular blood before it increased in the CSF at the transition to darkness, our second experiment appeared to support this proposal. However, our final study showed unequivocally that third ventricular levels of melatonin are 7-fold higher than lateral ventricle concentrations. This result suggests very strongly that the delay in the increase between CSF and plasma is due to the diffusion of melatonin from the pineal tissue to the third ventricle and not to the delay in melatonin entering first the blood and then the CSF.
How is it possible for lateral ventricle CSF melatonin levels to be elevated when the direction of CSF flow is away from the lateral ventricle? There are three possibilities, which may not be mutually exclusive. First, there may be some recirculation of CSF as previously proposed (23) . However, as lumbar and cisternal CSF concentrations appear to be consistently low, such recirculation would not explain why levels are elevated above plasma concentrations. Second, there may well be some retrograde blood flow into the choroid plexus, resulting in elevated melatonin concentrations in this structure and allowing melatonin to diffuse into the lateral ventricle down its concentration gradient. Third, the flow of CSF may not be unidirectional in the ventricles. A characteristic of the ventricular system evident during surgery (our personal observation) is a very strong pulsatility. During each pulse, it is probable that at least some third ventricular CSF enters the lateral ventricle. In this respect it is noteworthy that lateral ventricle melatonin concentrations started to rise after an increase was noted in the third ventricle in all three ewes. This last hypothesis would not only explain the lower melatonin level in the lateral ventricle compared with that in the third ventricle, but would also explain why it is still higher than that in the plasma. Does CSF melatonin have a function? The concept of humoral signals within the CSF was proposed many years ago (26) , and interest in this hypothesis has recently resurfaced (27, 28) . However, only indirect evidence exists to support the functional significance of CSF-borne factors (29) . Of all the biological molecules found in CSF, melatonin may be the first to validate this hypothesis. First, it should be noted that our study concurs with the few other CSF studies that consistently show that the nocturnal increase in CSF melatonin, like that in plasma melatonin, accurately reflects the duration of the night. CSF melatonin, therefore, contains the chemical code of day length, which is an essential prerequisite if it is to play a role in transducing circadian and photoperiodic information. Second, there will be a huge chemical gradient between CSF and the surrounding tissue and plasma. It is of interest, therefore, that of all of the factors detected in the CSF, melatonin has the highest ratio with respect to plasma (30) . Indeed, if plasma levels in the brain are reflected more accurately by carotid plasma concentrations and not jugular levels, then the CSF to plasma ratio is likely to be severalfold greater than we have reported in this study. This is because melatonin is degraded quite quickly (half-life in sheep is between 15-20 min) (31) , and the melatonin concentration in jugular plasma represents levels before its dilution in the peripheral circulation. Third, melatonin is small (mol wt, 233) and highly lipophilic, properties that would facilitate its movement through tissue. Indeed, in an earlier study we found that melatonin diffused through neural tissue up to 2 mm away from an isolated 0.45-mm diameter microimplant (32) .
The physiologically important target sites of melatonin remain largely unidentified. The detection of a surfeit of melatonin receptors in the pars tuberalis of the adenohypophysis suggested that this region could be a crucial site of action. Although the pars tuberalis may have other functions, we have recently shown that it is not responsible for transducing the effects of melatonin to the neuroendocrine reproductive axis (20, 22, 32) . Specifically, melatonin apposed to (22) or implanted directly in (32) the pars tuberalis has no effect, whereas melatonin microimplants in the hypothalamus (22, 32) and, more specifically, the premammilary hypothalamic region (20) potently affect reproductive functioning. This periventricular site extends laterally from the side of the third ventricle by only 2 mm. We believe strongly that melatonin will simply diffuse from the CSF in the third ventricle to its target in the premammilary hypothalamic region. This CSF hypothesis may appear at odds with studies showing that melatonin administered systemically to pin-ealectomized animals can entrain reproductive function (33, 34) . These studies showed unequivocally that melatonin was the primary endocrine factor involved in seasonal reproductive entrainment, but no extrapolation about the route used by melatonin to get from its source to its target is possible. This is because the levels produced in these melatonin replacement studies replicated jugular concentrations and not carotid artery levels, which, as mentioned, are likely to be severalfold lower (19) . Our laboratory is currently investigating the relationship among the carotid, jugular, and CSF compartments.
CSF melatonin has recently been proposed to play an interesting and potentially critical role in Alzheimer's disease (35, 36) . According to this hypothesis, the lower levels of CSF melatonin observed in Alzheimer's disease patients compared with normal controls (36, 37) mediate at least in part the loss of memory and other functions associated with this disease. This speculation is based on the recent report that melatonin is a powerful free radical scavenger and antioxidant (7, 8, 38) . Thus, reduced melatonin in CSF could lead to an increase in neuronal damage and death. It is worth noting, therefore, that although no experimental data exist to substantiate this proposal, recent studies on individuals suffering from Alzheimer's disease showed an improvement of several functions after melatonin replacement (9, 39, 40) . This novel area of research warrants significant further investigation.
A final point of note is the question of the physiological vs. pharmacological action of melatonin, which was recently reviewed very elegantly by Brzezinski (41) . Until now, this comparison has been made on the basis of the concentration detected in the peripheral circulation and how exogenous melatonin elevates this level. Our study provides compelling evidence that this question needs to be reevaluated, particularly with respect to neurally mediated functions.
In summary, we report for the first time that melatonin concentrations in the third ventricle are 20 times greater than those in the peripheral circulation and have a robust circadian profile, increasing and decreasing in accordance with darkness and light, respectively. Although melatonin increases in the plasma before it rises in the CSF, third ventricular melatonin does not appear to be derived from the peripheral circulation or the choroid plexus as previously proposed. Rather, CSF melatonin seems to originate directly from the pineal gland and may simply diffuse from this source into the third ventricle. The potential importance of CSF melatonin has recently been highlighted by the discovery of periventricular melatonin sites of action and the suggestion that melatonin may have a role in neurological diseases such as Alzheimer's.
